The Experts below are selected from a list of 18558 Experts worldwide ranked by ideXlab platform
Fuzhen Wang - One of the best experts on this subject based on the ideXlab platform.
-
the independent impact of newBorn <B>HepatitisB> B Vaccination on reducing hBv prevalence in china 1992 2006 a mathematical model analysis
Journal of Theoretical Biology, 2015Co-Authors: Peifeng Liang, Jian Zu, Xiaofeng Liang, Fuzhen Wang, Hao Li, Guihua ZhuangAbstract:ABstract OBjective To evaluate the independent impact of newBorn <B>HepatitisB> B Vaccination on reducing HBV prevalence in China, from its introduction in 1992 to 2006. Methods An age- and time-dependent discrete dynamic model was developed to simulate HBV transmission in China under the assumptions of no any change in interventions and only with newBorn Vaccination introduction, respectively. The initial conditions of the model were determined according to the national serosurvey in 1992. The simulated results were compared with the oBserved results of the national serosurvey in 2006, and the contriBution rate of newBorn Vaccination on reducing HBV prevalence was calculated overall and By Birth cohort. Results The total HBV prevalence would remain staBle through the 14-year period if no any change in interventions, But decrease year By year if only with newBorn Vaccination introduction. NewBorn Vaccination could account for more than 50% of the reduction of the total HBV prevalence, although the full 3-dose and timely Birth dose Vaccination coverage rates were low in the early years. The results By Birth cohort showed that the higher the two coverage rates, the higher contriBution rate on reducing HBV prevalence. For the 2005 Birth cohort which had high levels in the two coverage rates, the contriBution rate could reach more than 95%. Conclusion NewBorn <B>HepatitisB> B Vaccination from 1992 to 2006 in China had played the most important role in reducing HBV prevalence. NewBorn Vaccination with high full 3-dose and timely Birth dose coverage rates is the decisive factor in controlling <B>HepatitisB> B in China.
-
the doses of 10 μg should replace the doses of 5 μg in newBorn <B>HepatitisB> B Vaccination in china a cost effectiveness analysis
Vaccine, 2015Co-Authors: Zhenhao Ji, Peifeng Liang, Xiaofeng Liang, Fuzhen Wang, Qian Wu, Guihua ZhuangAbstract:ABstract OBjective To identify whether Chinese current series of three 5 μg doses for newBorn <B>HepatitisB> B Vaccination should Be replaced By the series of three 10 μg doses. Methods A cost-effectiveness analysis was conducted from the societal perspective Based on the constructed decision tree-Markov model. Model parameters were estimated from puBlished literatures, government documents and our surveys. The expected cost and effectiveness were compared Between the 3-dose 5 μg series (the 5 μg strategy) and the 3-dose 10 μg series (the 10 μg strategy), and the incremental cost-effectiveness ratio (ICER, additional cost per quality-adjusted life-years gained) was calculated. Threshold values of the efficacy difference of the two series for the ICER = 0, 1 and 3 times per capita gross domestic product were analyzed under different scenarios to understand whether the 10 μg strategy should replace the 5 μg strategy according to the recommendation of World Health Organization. Results The 10 μg strategy would Be cost-saving compared with the 5 μg strategy under the Base-case scenario. Under keeping all the other parameters at the Base-case values or further adjusting any one of them to the value most unfavoraBle to the 10 μg strategy, as long as the efficacy of 3-dose 10 μg series was slightly higher than that of 3-dose 5 μg series, the 10 μg strategy would Be cost-effective, highly cost-effective, or even cost-saving. Even under the most pessimistic scenario, i.e. all the other parameters, But the discount rate, at the values most unfavoraBle to the 10 μg strategy, the 10 μg strategy would Be cost-effective if the efficacy difference reached higher than 1.23 percentage point. Conclusion For newBorn <B>HepatitisB> B Vaccination in China, the 10 μg strategy should Be cost-effective, even more possiBly highly cost-effective or cost-saving compared with the current 5 μg strategy. The doses of 10 μg should Be considered to replace the doses of 5 μg in newBorn <B>HepatitisB> B Vaccination in China.
-
epidemiological serosurvey of <B>HepatitisB> B in china declining hBv prevalence due to <B>HepatitisB> B Vaccination
Vaccine, 2009Co-Authors: Xiaofeng Liang, Weizhong Yang, Longde Wang, Gang Cui, Fuqiang Cui, Yong Zhang, Jianhua Liu, Xiaohong Gong, Yuansheng Chen, Fuzhen WangAbstract:ABstract OBjective To determine the prevalence of <B>HepatitisB> B surface antigen (HBsAg), <B>HepatitisB> B surface antiBody (anti-HBs), and <B>HepatitisB> B core anti-Body (anti-HBc) in a representative population in China 14 years after introduction of <B>HepatitisB> B Vaccination of infants. Methods National serosurvey, with participants selected By multi-stage random sampling. Demographics and <B>HepatitisB> B Vaccination history collected By questionnaire and review of Vaccination records, and serum tested for HBsAg, antiBody to anti-HBc and anti-HBs By ELISA. Findings The weighted prevalences of HBsAg, anti-HBs and anti-HBc for Chinese population aged 1–59 years were 7.2%, 50.1%, 34.1%, respectively. HBsAg prevalence was greatly diminished among those age Conclusions China has already reached the national goal of reducing HBsAg prevalence to less than 1% among children under 5 years and has prevented an estimated 16–20 million HBV carriers through <B>HepatitisB> B Vaccination of infants. Immunization program should Be further strengthened to reach those remaining at highest risk.
-
epidemiological serosurvey of <B>HepatitisB> B in china declining hBv prevalence due to <B>HepatitisB> B Vaccination
Vaccine, 2009Co-Authors: Xiaofeng Liang, Fuzhen Wang, Weizhong Yang, Longde Wang, Yong Zhang, Xiaohong Gong, Yuansheng Chen, Shengli Bi, Hui Zheng, Feng WangAbstract:OBJECTIVE: To determine the prevalence of <B>HepatitisB> B surface antigen (HBsAg), <B>HepatitisB> B surface antiBody (anti-HBs), and <B>HepatitisB> B core anti-Body (anti-HBc) in a representative population in China 14 years after introduction of <B>HepatitisB> B Vaccination of infants. METHODS: National serosurvey, with participants selected By multi-stage random sampling. Demographics and <B>HepatitisB> B Vaccination history collected By questionnaire and review of Vaccination records, and serum tested for HBsAg, antiBody to anti-HBc and anti-HBs By ELISA. FINDINGS: The weighted prevalences of HBsAg, anti-HBs and anti-HBc for Chinese population aged 1-59 years were 7.2%, 50.1%, 34.1%, respectively. HBsAg prevalence was greatly diminished among those age <15 years compared to that found in the 1992 national serosurvey, and among children age <5 years was only 1.0% (90% reduction). Reduced HBsAg prevalence was strongly associated with Vaccination among all age groups. HBsAg risk in adults was associated with male sex, Western region, and certain ethnic groups and occupations while risk in children included Birth at home or smaller hospitals, older age, and certain ethnic groups (Zhuang and other). CONCLUSIONS: China has already reached the national goal of reducing HBsAg prevalence to less than 1% among children under 5 years and has prevented an estimated 16-20 million HBV carriers through <B>HepatitisB> B Vaccination of infants. Immunization program should Be further strengthened to reach those remaining at highest risk.
-
evaluation of the impact of <B>HepatitisB> B Vaccination among children Born during 1992 2005 in china
The Journal of Infectious Diseases, 2009Co-Authors: Xiaofeng Liang, Weizhong Yang, Longde Wang, Gang Cui, Fuqiang Cui, Yong Zhang, Jianhua Liu, Xiaohong Gong, Yuansheng Chen, Fuzhen WangAbstract:Background. Endemic <B>HepatitisB> B virus (HBV) infection is a serious health proBlem in China. <B>HepatitisB> B Vaccination of infants was introduced in 1992 and was progressively expanded during the suBsequent 15 years. Methods. We conducted a national serosurvey, with participants selected By multiple-stage random sampling. Demographic characteristics and <B>HepatitisB> B Vaccination history were collected By a questionnaire and a review of Vaccination records, and serum specimens were tested for <B>HepatitisB> B surface antigen, antiBody to <B>HepatitisB> B core antigen, and <B>HepatitisB> B surface antiBody By enzyme-linked immunosorBent assay. Results. <B>HepatitisB> B vaccine coverage (3 doses) increased from 30.0% for children Born in 1992 to 93.4% for children Born in 2005. Receipt of a timely Birth dose increased from 22.2% to 82.6% for children Born during this interval. Multivariate analysis showed that older age, western and rural residence, Birth at home, and certain ethnicities were risk factors for underVaccination with Both full vaccine series and timely Birth dose. The prevalence of <B>HepatitisB> B surface antigen was reduced to 2.1% among all children and 1.0% among children Born after 1999. The efficacy of <B>HepatitisB> B Vaccination with a timely Birth dose was 88.3%. Conclusions. <B>HepatitisB> B vaccine has Been successfully integrated into routine infant immunization in China, now reaching most infants within 24 h after Birth, and the prevalence of <B>HepatitisB> B surface antigen has Been greatly reduced among children Born after 1992.
Xiaofeng Liang - One of the best experts on this subject based on the ideXlab platform.
-
the independent impact of newBorn <B>HepatitisB> B Vaccination on reducing hBv prevalence in china 1992 2006 a mathematical model analysis
Journal of Theoretical Biology, 2015Co-Authors: Peifeng Liang, Jian Zu, Xiaofeng Liang, Fuzhen Wang, Hao Li, Guihua ZhuangAbstract:ABstract OBjective To evaluate the independent impact of newBorn <B>HepatitisB> B Vaccination on reducing HBV prevalence in China, from its introduction in 1992 to 2006. Methods An age- and time-dependent discrete dynamic model was developed to simulate HBV transmission in China under the assumptions of no any change in interventions and only with newBorn Vaccination introduction, respectively. The initial conditions of the model were determined according to the national serosurvey in 1992. The simulated results were compared with the oBserved results of the national serosurvey in 2006, and the contriBution rate of newBorn Vaccination on reducing HBV prevalence was calculated overall and By Birth cohort. Results The total HBV prevalence would remain staBle through the 14-year period if no any change in interventions, But decrease year By year if only with newBorn Vaccination introduction. NewBorn Vaccination could account for more than 50% of the reduction of the total HBV prevalence, although the full 3-dose and timely Birth dose Vaccination coverage rates were low in the early years. The results By Birth cohort showed that the higher the two coverage rates, the higher contriBution rate on reducing HBV prevalence. For the 2005 Birth cohort which had high levels in the two coverage rates, the contriBution rate could reach more than 95%. Conclusion NewBorn <B>HepatitisB> B Vaccination from 1992 to 2006 in China had played the most important role in reducing HBV prevalence. NewBorn Vaccination with high full 3-dose and timely Birth dose coverage rates is the decisive factor in controlling <B>HepatitisB> B in China.
-
the doses of 10 μg should replace the doses of 5 μg in newBorn <B>HepatitisB> B Vaccination in china a cost effectiveness analysis
Vaccine, 2015Co-Authors: Zhenhao Ji, Peifeng Liang, Xiaofeng Liang, Fuzhen Wang, Qian Wu, Guihua ZhuangAbstract:ABstract OBjective To identify whether Chinese current series of three 5 μg doses for newBorn <B>HepatitisB> B Vaccination should Be replaced By the series of three 10 μg doses. Methods A cost-effectiveness analysis was conducted from the societal perspective Based on the constructed decision tree-Markov model. Model parameters were estimated from puBlished literatures, government documents and our surveys. The expected cost and effectiveness were compared Between the 3-dose 5 μg series (the 5 μg strategy) and the 3-dose 10 μg series (the 10 μg strategy), and the incremental cost-effectiveness ratio (ICER, additional cost per quality-adjusted life-years gained) was calculated. Threshold values of the efficacy difference of the two series for the ICER = 0, 1 and 3 times per capita gross domestic product were analyzed under different scenarios to understand whether the 10 μg strategy should replace the 5 μg strategy according to the recommendation of World Health Organization. Results The 10 μg strategy would Be cost-saving compared with the 5 μg strategy under the Base-case scenario. Under keeping all the other parameters at the Base-case values or further adjusting any one of them to the value most unfavoraBle to the 10 μg strategy, as long as the efficacy of 3-dose 10 μg series was slightly higher than that of 3-dose 5 μg series, the 10 μg strategy would Be cost-effective, highly cost-effective, or even cost-saving. Even under the most pessimistic scenario, i.e. all the other parameters, But the discount rate, at the values most unfavoraBle to the 10 μg strategy, the 10 μg strategy would Be cost-effective if the efficacy difference reached higher than 1.23 percentage point. Conclusion For newBorn <B>HepatitisB> B Vaccination in China, the 10 μg strategy should Be cost-effective, even more possiBly highly cost-effective or cost-saving compared with the current 5 μg strategy. The doses of 10 μg should Be considered to replace the doses of 5 μg in newBorn <B>HepatitisB> B Vaccination in China.
-
epidemiological serosurvey of <B>HepatitisB> B in china declining hBv prevalence due to <B>HepatitisB> B Vaccination
Vaccine, 2009Co-Authors: Xiaofeng Liang, Weizhong Yang, Longde Wang, Gang Cui, Fuqiang Cui, Yong Zhang, Jianhua Liu, Xiaohong Gong, Yuansheng Chen, Fuzhen WangAbstract:ABstract OBjective To determine the prevalence of <B>HepatitisB> B surface antigen (HBsAg), <B>HepatitisB> B surface antiBody (anti-HBs), and <B>HepatitisB> B core anti-Body (anti-HBc) in a representative population in China 14 years after introduction of <B>HepatitisB> B Vaccination of infants. Methods National serosurvey, with participants selected By multi-stage random sampling. Demographics and <B>HepatitisB> B Vaccination history collected By questionnaire and review of Vaccination records, and serum tested for HBsAg, antiBody to anti-HBc and anti-HBs By ELISA. Findings The weighted prevalences of HBsAg, anti-HBs and anti-HBc for Chinese population aged 1–59 years were 7.2%, 50.1%, 34.1%, respectively. HBsAg prevalence was greatly diminished among those age Conclusions China has already reached the national goal of reducing HBsAg prevalence to less than 1% among children under 5 years and has prevented an estimated 16–20 million HBV carriers through <B>HepatitisB> B Vaccination of infants. Immunization program should Be further strengthened to reach those remaining at highest risk.
-
epidemiological serosurvey of <B>HepatitisB> B in china declining hBv prevalence due to <B>HepatitisB> B Vaccination
Vaccine, 2009Co-Authors: Xiaofeng Liang, Fuzhen Wang, Weizhong Yang, Longde Wang, Yong Zhang, Xiaohong Gong, Yuansheng Chen, Shengli Bi, Hui Zheng, Feng WangAbstract:OBJECTIVE: To determine the prevalence of <B>HepatitisB> B surface antigen (HBsAg), <B>HepatitisB> B surface antiBody (anti-HBs), and <B>HepatitisB> B core anti-Body (anti-HBc) in a representative population in China 14 years after introduction of <B>HepatitisB> B Vaccination of infants. METHODS: National serosurvey, with participants selected By multi-stage random sampling. Demographics and <B>HepatitisB> B Vaccination history collected By questionnaire and review of Vaccination records, and serum tested for HBsAg, antiBody to anti-HBc and anti-HBs By ELISA. FINDINGS: The weighted prevalences of HBsAg, anti-HBs and anti-HBc for Chinese population aged 1-59 years were 7.2%, 50.1%, 34.1%, respectively. HBsAg prevalence was greatly diminished among those age <15 years compared to that found in the 1992 national serosurvey, and among children age <5 years was only 1.0% (90% reduction). Reduced HBsAg prevalence was strongly associated with Vaccination among all age groups. HBsAg risk in adults was associated with male sex, Western region, and certain ethnic groups and occupations while risk in children included Birth at home or smaller hospitals, older age, and certain ethnic groups (Zhuang and other). CONCLUSIONS: China has already reached the national goal of reducing HBsAg prevalence to less than 1% among children under 5 years and has prevented an estimated 16-20 million HBV carriers through <B>HepatitisB> B Vaccination of infants. Immunization program should Be further strengthened to reach those remaining at highest risk.
-
evaluation of the impact of <B>HepatitisB> B Vaccination among children Born during 1992 2005 in china
The Journal of Infectious Diseases, 2009Co-Authors: Xiaofeng Liang, Weizhong Yang, Longde Wang, Gang Cui, Fuqiang Cui, Yong Zhang, Jianhua Liu, Xiaohong Gong, Yuansheng Chen, Fuzhen WangAbstract:Background. Endemic <B>HepatitisB> B virus (HBV) infection is a serious health proBlem in China. <B>HepatitisB> B Vaccination of infants was introduced in 1992 and was progressively expanded during the suBsequent 15 years. Methods. We conducted a national serosurvey, with participants selected By multiple-stage random sampling. Demographic characteristics and <B>HepatitisB> B Vaccination history were collected By a questionnaire and a review of Vaccination records, and serum specimens were tested for <B>HepatitisB> B surface antigen, antiBody to <B>HepatitisB> B core antigen, and <B>HepatitisB> B surface antiBody By enzyme-linked immunosorBent assay. Results. <B>HepatitisB> B vaccine coverage (3 doses) increased from 30.0% for children Born in 1992 to 93.4% for children Born in 2005. Receipt of a timely Birth dose increased from 22.2% to 82.6% for children Born during this interval. Multivariate analysis showed that older age, western and rural residence, Birth at home, and certain ethnicities were risk factors for underVaccination with Both full vaccine series and timely Birth dose. The prevalence of <B>HepatitisB> B surface antigen was reduced to 2.1% among all children and 1.0% among children Born after 1999. The efficacy of <B>HepatitisB> B Vaccination with a timely Birth dose was 88.3%. Conclusions. <B>HepatitisB> B vaccine has Been successfully integrated into routine infant immunization in China, now reaching most infants within 24 h after Birth, and the prevalence of <B>HepatitisB> B surface antigen has Been greatly reduced among children Born after 1992.
Alessandro Zanetti - One of the best experts on this subject based on the ideXlab platform.
-
<B>HepatitisB> B Vaccination
Human Vaccines & Immunotherapeutics, 2015Co-Authors: Luisa Romano, Sara Paladini, C Galli, Giovanni Raimondo, Teresa Pollicino, Alessandro ZanettiAbstract:<B>HepatitisB> B virus is a worldwide leading cause of acute and chronic liver disease including cirrhosis and hepatocellular carcinoma. Effective vaccines have Been availaBle since the early ‘80s and Vaccination has proved highly successful in reducing the disease Burden, the development of the carrier state and the HB-related morBidity and mortality in the countries where Vaccination has Been implemented. Neutralizing (protective) antiBodies (anti-HBs) induced By Vaccination are targeted largely towards the amino acid hydrophilic region, referred to as the common a determinant which is present on the outer protein coat or surface antigen (HBsAg), spanning amino acids 124–149. This provides protection against all HBV genotypes (from A to H) and is responsiBle for the Broad immunity afforded By <B>HepatitisB> B Vaccination. Thus, alterations of residues within this region of the surface antigen may determine conformational changes that can allow replication of the mutated HBV in vaccinated people. An important mu...
-
the changing face of the epidemiology of type a B and d viral <B>HepatitisB> in italy following the implementation of Vaccination
Vaccine, 2009Co-Authors: Luisa Romano, Sara Paladini, A Zappa, Catia Tagliacarne, Alessandro ZanettiAbstract:The morBidity and mortality rates of viral <B>HepatitisB> A, B and Delta have dramatically dropped in Italy during the last decades. Thanks to the general improvements in hygiene and sanitation, <B>HepatitisB> A has shifted from a high to an intermediate/low endemicity status. Vaccination against <B>HepatitisB> A is recommended to people at increased risk, including travellers to endemic areas, military personnel and individuals at occupational risk. The implementation of universal anti-<B>HepatitisB> B Vaccination of infants and adolescents has resulted in a dramatic decline in disease Burden and in the carrier rate. An additional Benefit of <B>HepatitisB> B Vaccination is that <B>HepatitisB> Delta has also suBstantially declined.
-
impact of <B>HepatitisB> B Vaccination in a highly endemic area of south italy and long term duration of anti hBs antiBody in two cohorts of vaccinated individuals
Vaccine, 2007Co-Authors: Giuliano Da Villa, Luisa Romano, Alessio Sepe, Raffaele Iorio, Nunzio Paribello, A Zappa, Alessandro ZanettiAbstract:The aims of this study were to evaluate the impact of <B>HepatitisB> B Vaccination on the changing pattern of HBV infection in a former hyperendemic area (Afragola, South Italy), and to assess the long-term persistence of anti-HBs in two cohorts of individuals vaccinated as infants 18 and 23 years ago. Our data shows a significant decline in the prevalence of <B>HepatitisB> B virus (HBV) markers in the general population from 1978 to 2006 (HBsAg: 13.4% versus 0.91%; anti-HBc: 66.9% versus 7.6%; p<0.001). Data from two cohorts of vaccinees provides further evidence regarding the long-term persistence of vaccine-induced anti-HBs. Data here reported indicates that the implementation of Vaccination had a great impact in the control and prevention of <B>HepatitisB> B in Italy.
-
long term immunogenicity of <B>HepatitisB> B Vaccination and policy for Booster an italian multicentre study
The Lancet, 2005Co-Authors: Alessandro Zanetti, Luisa Romano, Andrea Mariano, R Damelio, Maria Chironna, Rosa Cristina Coppola, Mario Cuccia, R Mangione, Fosca Marrone, Francesco Saverio NegroneAbstract:Summary Background Universal anti-<B>HepatitisB>-B Vaccination of infants and adolescents was implemented in Italy in 1991. We undertook a multicentre study in previously vaccinated individuals to assess the duration of immunity and need for Booster, over 10 years after Vaccination. Methods In 1212 children and 446 Italian Air Force recruits vaccinated as infants and adolescents, respectively, we measured the concentrations of antiBodies to <B>HepatitisB>-B surface antigen (anti-HBs) and the presence of antiBodies to <B>HepatitisB>-B core antigen (anti-HBc) at enrolment; postimmunisation values were not availaBle. Individuals positive for anti-HBc were tested for <B>HepatitisB> B surface antigen (HBsAg) and <B>HepatitisB> B viral DNA. Individuals with anti-HBs concentrations at 10 IU/L or more were regarded as protected; those with antiBody less than 10 IU/L were given a Booster dose and retested 2 weeks later. Individuals showing postBooster anti-HBs concentrations of less than 10 IU/L were offered two additional vaccine doses and retested 1 month after the third dose. Findings Protective anti-HBs concentrations were retained in 779 (64%, 95% CI 61·6–67) children and 398 (89%, 86·4–92·1) recruits. We recorded antiBody amounts of less than 10 IU/L in 433 children (36%, 33–38·4) and 48 (11%, 7·9–13·6) recruits. One child and four recruits were positive for anti-HBc, But negative for HBsAg and <B>HepatitisB> B viral DNA. AntiBody concentrations were higher in recruits than in children (geometric mean titre 234·8 IU/L vs 32·1 IU/L, p=0·0001). 332 (97%) of 342 children and 46 (96%) of 48 recruits who received a Booster showed an anamnestic response, whereas ten (3%) children and two (4%) recruits remained negative for anti-HBs or had antiBody concentrations of less than 10 IU/L. PreBooster and postBooster antiBody titres were strongly correlated with each other in Both groups. All individuals given two additional vaccine doses (eight children and two recruits) showed anti-HBs amounts of more than 10 IU/L at 1 month after Vaccination. Interpretation Strong immunological memory persists more than 10 years after immunisation of infants and adolescents with a primary course of Vaccination. Booster doses of vaccine do not seem necessary to ensure long-term protection.
Harold S. Margolis - One of the best experts on this subject based on the ideXlab platform.
-
a comprehensive immunization strategy to eliminate transmission of <B>HepatitisB> B virus infection in the united states recommendations of the advisory committee on immunization practices acip part 1 immunization of infants children and adolescents
Morbidity and Mortality Weekly Report, 2005Co-Authors: Eric E Mast, Beth P Bell, Harold S. Margolis, Anthony E Fiore, Edward W Brink, Susan T Goldstein, Susan A Wang, Linda A Moyer, Miriam J AlterAbstract:This report is the first of a two-part statement from the Advisory Committee on Immunization Practices (ACIP) that updates the strategy to eliminate <B>HepatitisB> B virus (HBV) transmission in the United States. The report provides updated recommendations to improve prevention of perinatal and early childhood HBV transmission, including implementation of universal infant Vaccination Beginning at Birth, and to increase vaccine coverage among previously unvaccinated children and adolescents. Strategies to enhance implementation of the recommendations include 1) estaBlishing standing orders for administration of <B>HepatitisB> B Vaccination Beginning at Birth; 2) instituting delivery hospital policies and procedures and case management programs to improve identification of and administration of immunoprophylaxis to infants Born to mothers who are <B>HepatitisB> B surface antigen (HBsAg) positive and to mothers with unknown HBsAg status at the time of delivery; and 3) implementing Vaccination record reviews for all children aged 11-12 years and children and adolescents aged <19 years who were Born in countries with intermediate and high levels of HBV endemicity, adopting <B>HepatitisB> B vaccine requirements for school entry, and integrating <B>HepatitisB> B Vaccination services into settings that serve adolescents. The second part of the ACIP statement, which will include updated recommendations and strategies to increase <B>HepatitisB> B Vaccination of adults, will Be puBlished separately.
-
AntiBody levels and protection after <B>HepatitisB> B Vaccination: results of a 15-year follow-up
Annals of internal medicine, 2005Co-Authors: Brian J. Mcmahon, Dana Bruden, Kenneth M. Petersen, Lisa R. Bulkow, Alan J. Parkinson, Omana V. Nainan, Marina L. Khristova, Carolyn Zanis, Helen Peters, Harold S. MargolisAbstract:The duration of protection afforded By <B>HepatitisB> B Vaccination is unknown. In this cohort of Alaska Natives who received Vaccination against <B>HepatitisB>, antiBody levels decreased over a 15-year peri...
-
antiBody levels and protection after <B>HepatitisB> B Vaccination results of a 15 year follow up
Annals of Internal Medicine, 2005Co-Authors: Brian J. Mcmahon, Dana Bruden, Kenneth M. Petersen, Lisa R. Bulkow, Alan J. Parkinson, Omana V. Nainan, Marina L. Khristova, Carolyn Zanis, Helen Peters, Harold S. MargolisAbstract:Background: The duration of protection afforded By <B>HepatitisB> B Vaccination is unknown. OBjective: To determine antiBody persistence and protection from <B>HepatitisB> B virus (HBV) infection. Design: Prospective cohort study. Setting: 15 villages in southwest Alaska. Participants: 1578 Alaska Natives vaccinated at age 6 months or older. Intervention: During 1981-1982, participants received 3 doses of plasma-derived <B>HepatitisB> B vaccine. This cohort was followed annually over the first 11 years, and 841 (53%) persons were tested at 15 years. Measurements: AntiBody to <B>HepatitisB> B surface antigen (anti-HBs), markers of HBV infection, and testing to identify HBV variants. Results: Levels of anti-HBs in the cohort decreased from a geometric mean concentration of 822 mlU/mL after Vaccination to 27 mIU/mL at 15 years. Initial anti-HBs level, older age at Vaccination, and male sex were associated with persistence of higher anti-HBs levels at 15 years when analyzed By a longitudinal linear mixed model. After adjustment for initial anti-HBs level and sex, those vaccinated at age 6 months to 4 years had the lowest anti-HBs level at 15 years. Asymptomatic Breakthrough infections were detected in 16 participants and occurred more frequently in persons who did not respond to Vaccination than those who responded (P= 0.01). Among infected persons with viremia, 2 were infected with wild-type HBV and 4 had HBV surface glycoprotein variants, generally accompanied By wild-type HBV. Limitations: The loss of participants to follow-up at 15 years was 47%. However, characteristics of persons tested were similar to those of persons lost to follow-up. Conclusions: <B>HepatitisB> B Vaccination strongly protected against infection for at least 15 years in all age groups. AntiBody levels decreased the most among persons immunized at 4 years of age or younger.
Eyasu H Teshale - One of the best experts on this subject based on the ideXlab platform.
-
<B>HepatitisB> B Vaccination for healthcare personnel in american samoa pre implementation survey for policy decision
Epidemiology and Infection, 2014Co-Authors: H Roberts, Roxanne E Williams, Y Masunufaleafaga, Jan Drobeniuc, Saleem Kamili, Eyasu H TeshaleAbstract:American Samoa does not have a <B>HepatitisB> B Vaccination policy for healthcare personnel (HCP). Consequently, <B>HepatitisB> B has remained a health threat to HCP. In this study, we performed a cross-sectional study and examined demographic and risk information and <B>HepatitisB> B Vaccination, testing, and serostatus in hospital employees in American Samoa. Of 604 hospital employees, 231 (38·2%) participated, and of these, 158 (68·4%) were HCP. Of HCP participants, 1·9% had chronic <B>HepatitisB> B infection, 36·1% were susceptiBle, and 60·8% were immune. Nearly half of HCP participants reported history of needlestick injury. Overall, participants' knowledge of their <B>HepatitisB> B infection and Vaccination status was low. These data support the adoption of a <B>HepatitisB> B Vaccination policy for HCP By American Samoa, as currently recommended By the World Health Organization and the US Centers for Disease Control and Prevention. Adherence to the policy could Be monitored as a way to measure protection.
-
short report <B>HepatitisB> B Vaccination for healthcare personnel in american samoa pre implementation survey for policy decision
2014Co-Authors: H Roberts, Y Masunufaleafaga, Jan Drobeniuc, Eyasu H Teshale, Pago PagoAbstract:SUMMARY American Samoa does not have a <B>HepatitisB> B Vaccination policy for healthcare personnel (HCP). Consequently, <B>HepatitisB> B has remained a health threat to HCP. In this study, we performed a cross-sectional study and examined demographic and risk information and <B>HepatitisB> B Vaccination, testing, and serostatus in hospital employees in American Samoa. Of 604 hospital employees, 231 (38·2%) participated, and of these, 158 (68·4%) were HCP. Of HCP participants, 1·9% had chronic <B>HepatitisB> B infection, 36·1% were susceptiBle, and 60·8% were immune. Nearly half of HCP participants reported history of needlestick injury. Overall, participants’ knowledge of their <B>HepatitisB> B infection and Vaccination status was low. These data support the adoption of a <B>HepatitisB> B Vaccination policy for HCP By American Samoa, as currently recommended By the World Health Organization and the US Centers for Disease Control and Prevention. Adherence to the policy could Be monitored as a way to measure protection.